Endocrine Pathology

, Volume 10, Issue 2, pp 103–108 | Cite as

Expression of leukemia inhibitory factor in craniopharyngioma

  • Ami Tran
  • Kalman Kovacs
  • Lucia Stefaneanu
  • George Kontogeorgos
  • Bernd W. Scheithauer
  • Shlomo Melmed
Clinical Research


It has recently been reported that overexpression of leukemia inhibitory factor (LIF) in mice transgenic for LIF causes invagination of the anterior wall of Rathke’s pouch leading to the formation of cysts lined by LIF immunoreactive epithelial cells. Strong immunoreactivity was also found in human Rathke’s cleft cysts. Because such cysts and craniopharyngiomas share a common histogenesis, we raised the question of whether LIF is also expressed in craniopharyngioma.

Fourteen histologically verified craniopharyngiomas of adamantinomatous type were examined for LIF immunoreactivity using the streptavidin-biotin-peroxidase complex method. Rabbit-anti-LIF antibody dilution 1:40) was applied to tissues having undergone antigen retrieval (microwaving in citrate buffer at pH 6). For positive control, nontumorous pituitary tissues were used. Primary antibody substituted with phosphate-buffered saline served as a negative control.

By immunocytochemistry, the epithelial cells of all 14 craniopharyngiomas were LIF immunoreactive, showing varying degrees of staining intensity. In comparison, the connective tissue components of the tumors were immunonegative.

Our study provides evidence that LIF is expressed in the epithelial cells of craniopharyngioma. Further investigation is required to elucidate the possible role of LIF in the development and progression of craniopharyngiomas.

Key Words

Craniopharyngioma immunocytochemistry leukemia inhibitory factor pituitary Rathke’s cleft cyst 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tsagarakis S, Kontogeorgos G, Kovacs K. The role of cytokines in the normal and neoplastic pituitary. Crit Rev Oncol/Hematol, in press.Google Scholar
  2. 2.
    Dhingra K, Sahin A, Emami K, Hortobagyi GN, Estrov Z. Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism. Breast Cancer Res Treat 48:165–174, 1998.PubMedCrossRefGoogle Scholar
  3. 3.
    Patterson PH. Leukemia inhibitory factor, a cytokine at the interface between neurobiology and immunology. Proc Natl Acad Sci USA 91:7833–7835, 1994.PubMedCrossRefGoogle Scholar
  4. 4.
    Auernhammer CJ, Chesnokova V, Melmed S. Leukemia inhibitory factor modulates interleukin-1β-induced activation of the hypothalamo-pituitary-adrenal-axis. Endocrinology 139:2201–2208, 1998.PubMedCrossRefGoogle Scholar
  5. 5.
    Ferrara N, Winer J, Henzel WJ. Pituitary follicular cells secrete an inhibitor of aortic endothelial cell growth: indentification as leukemia inhibitory factor. Proc Natl Acad Sci USA 89:698–702, 1992.PubMedCrossRefGoogle Scholar
  6. 6.
    Akita S, Webster J, Ren SG, Takino H, Said J, Zand O, et al. Human and murine pituitary expression of leukemia inhibitory factor. J Clin Invest 95:1288–1298, 1995.PubMedCrossRefGoogle Scholar
  7. 7.
    Chesnokova V, Auernhammer CJ, Melmed S. Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology 139:2209–2216, 1998.PubMedCrossRefGoogle Scholar
  8. 8.
    Akita S, Redhead C, Stefaneanu L, Fine J, Tampanaru Sarmesiu A, Kovacs K, et al. Pituitary-directed leukemia inhibitory factor transgene forms Rathke’s cleft cysts and impairs adult pituitary funcition. A model for human pituitary Rathke’s cysts. J Clin Invest 99:2462–2469, 1997.PubMedGoogle Scholar
  9. 9.
    Yamada H, Haratake J, Narasaki T, Oda TA. Embryonal craniopharyngioma case report of the morphogenesis of craniopharyngioma. Cancer 75:2971–2977, 1995.PubMedCrossRefGoogle Scholar
  10. 10.
    Scheithauer BW. Pathology of the pituitary and seller region: exclusive of pituitary adenoma. Ann Pathol 20:67–155, 1985.Google Scholar
  11. 11.
    Lohmori T, Okada K, Tabei R. Immunoreactivity to neurohormonal polypeptide in colorectal carcinomas and tumor-neighboring mucosa, and its significance. Arch Pathol Lab Med 120:560–568, 1996.Google Scholar
  12. 12.
    Ichikawa, Y. Differentiation of a cell line of Myeloid leukemia. J Cell Physiol 74: 223–234, 1969.PubMedCrossRefGoogle Scholar
  13. 13.
    Metcalf D., Clonal analysis of the action of GM-CSF on the proliferation and differentiation of myelomonocytic leukemic cells. Int J Cancer 24:616–623, 1979.PubMedCrossRefGoogle Scholar
  14. 14.
    Gearing DP, Gough NM, King JA, Hiltion DJ, Nicola NA, Simpson RJ, et al. Molecular cloning and expression of cDNA encoding a murine myeloid leukemia inhibitory factor (LIF). EMBO J 6:3995–4002, 1987.PubMedGoogle Scholar
  15. 15.
    Taupin JL, Pitard V, Dechanet J, Miossec V, Gualde N, Moreau JF. Leukemia inhibitory factor: part of a large ingathering family Int Rev Immunol 16:397–426, 1998.PubMedGoogle Scholar
  16. 16.
    Metcalf D. The leukemia inhibitory factor (LIF). Int J Cell Cloning 9:95–108, 1991.PubMedCrossRefGoogle Scholar
  17. 17.
    Bhatt H, Brunet LJ, Stewart CL. Uterine expression of leukemia inhibitory factor coincides with the onset of blastocyst implantation. Proc Natl Acad Sci USA 88:11,408–11,412, 1991CrossRefGoogle Scholar
  18. 18.
    Bamberger AM, Jenatschke S, Erdmann I, Heirircih MS. Progestin-dependent stimulation of the human LIF promoter in SKUT-1b uterine tumor cells. J Reprod Immun 33:189–201, 1997.CrossRefGoogle Scholar
  19. 19.
    Iseki H, Kajimura N, Ohue C, Tanaka R, Akiyama Y, Yamaguchi K. Cytokine production in five tumor cell lines with activity to induce cancer cachexia syndrome in nude mice. Jpn J Cancer Res 86:562–567, 1995.PubMedGoogle Scholar
  20. 20.
    Gascan H, Anegon I, Praloran V, Naulet J, Godard A, Soulillou JP, et al. Constitutive production of human interleukin for DA cells/ leukemia inhibitory factor by human tumor cell lines derived from various tissues. J Immunol 144:2592–2598, 1990.PubMedGoogle Scholar
  21. 21.
    Kellokumpu-Lehtinen P, Talpaz M, Harris D, Van Q, Kurzrock R, Estrov Z. Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. Int J Cancer 66:515–519, 1996.PubMedCrossRefGoogle Scholar
  22. 22.
    Ikeda H, Suzuki J, Sasano N, Niizuma H. The development and morphogenesis of the human pituitary gland. Anat Embryol 178:327–336, 1988.PubMedCrossRefGoogle Scholar
  23. 23.
    Burger PC, Scheithauer BW, Vogel FS. Region of the sella turcica: seller and supracellar cysts. In: Surgical pathology of the nervous system and its coverings, 3rd ed. New York: Churchill Livingstone, 1991; 546–549.Google Scholar
  24. 24.
    Harrison MJ, Morgello S, Post KD. Epithelial cystic lesions of the seller and parasellar region: a continuum of ectodermal derivatives? J Neurosurg 80:1018–1025, 1994.PubMedCrossRefGoogle Scholar
  25. 25.
    Crotty T, Scheithauer BW, Young WF, Davis D, Miller G, Burger PC. Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg 83: 206–214, 1995.PubMedGoogle Scholar

Copyright information

© Humana Press Inc 1999

Authors and Affiliations

  • Ami Tran
    • 4
    • 1
  • Kalman Kovacs
    • 4
    • 1
  • Lucia Stefaneanu
    • 4
    • 1
  • George Kontogeorgos
    • 4
    • 1
  • Bernd W. Scheithauer
    • 2
  • Shlomo Melmed
    • 3
  1. 1.Department of Medicine, St., Michaels HospitalUniversity of TorontoTorontoCanada
  2. 2.Department of Laboratory Medicine and PathologyMayo ClinicRochester
  3. 3.Division of Endocrinology and Metabolism Cedars-Sinai Research InstituteUCLA School of MedicineLos Angeles
  4. 4.Department of PathologySt. Michael’s HospitalTorontoCanada

Personalised recommendations